Ruqayya Saad Hamid (1), Raghad Hazem Alabbasy (2), Azhar Khalaf Alazzawi (3)
Gastric ulcers remain a major gastrointestinal disorder with significant global morbidity, frequently linked to hematological disturbances and systemic complications. While Helicobacter pylori infection and non-steroidal anti-inflammatory drug (NSAID) use are the leading causes of gastric ulcers, less attention has been given to their systemic impact, particularly on renal function and hematological status. Limited studies have explored the combined histological, hematological, and renal alterations in gastric ulcer patients, especially in developing regions. This study aimed to evaluate gastric mucosal histopathology in ulcer patients and investigate its association with hemoglobin levels, packed cell volume, and kidney function. Ninety participants were studied, including 60 with gastric ulcers and 30 controls. Patients demonstrated significantly reduced hemoglobin (11.55 ± 2.31 g/dL) and packed cell volume (36.37 ± 7.51%) compared with controls (p ≤ 0.05). Kidney function analysis revealed elevated urea (32.93 ± 9.41 mg/dL) and creatinine (0.816 ± 0.205 mg/dL) in patients versus controls (p ≤ 0.05). Histological examination of 100 gastric biopsies showed inflammation in 93% of cases, with active chronic inflammation in 59%, and H. pylori infection in 66% of samples. This is one of the first studies in Iraq to link histological gastric ulcer findings with both hematological parameters and renal function, providing an integrative view of disease impact. The findings highlight the need for comprehensive management of gastric ulcer patients, including regular monitoring of hematological and renal markers, alongside histopathological evaluation, to prevent systemic complications and improve outcomes.
Highlights:
[1] H. Gong, N. Zhao, C. Zhu, L. Luo, and S. Liu, “Treatment of gastric ulcer, traditional Chinese medicine may be a better choice,” J. Ethnopharmacol., vol. 324, p. 117793, 2024, doi: 10.1016/j.jep.2024.117793.
[2] A. H. Khan, M. A. Dar, and M. A. Mir, “Gastric ulcer: an overview,” Int. J. Curr. Res. Physiol. Pharmacol., vol. 7, no. 1, pp. 1–7, 2023. [Online]. Available: http://ijcrpp.com
[3] A. Barchi, C. Miraglia, A. Violi, G. Cambiè, A. Nouvenne, M. Capasso, G. Leandro, T. Meschi, G. L. De’ Angelis, and F. Di Mario, “A non-invasive method for the diagnosis of upper GI diseases,” Acta Biomed., vol. 89, no. 8-S, pp. 40–43, 2018.
[4] J. K. Y. Hooi, W. Y. Lai, W. K. Ng, M. M. Y. Suen, F. E. Underwood, D. Tanyingoh, P. Malfertheiner, D. Y. Graham, V. W. S. Wong, J. C. Y. Wu, F. K. L. Chan, J. J. Y. Sung, G. G. Kaplan, and S. C. Ng, “Global prevalence of Helicobacter pylori infection: Systematic review and meta-analysis,” Gastroenterology, vol. 153, no. 2, pp. 420–429, 2017.
[5] A. Ceylan, E. Kirimi, O. Tuncer, K. Türkdoğan, S. Ariyuca, and N. Ceylan, “Prevalence of Helicobacter pylori in children and their family members in a district in Turkey,” J. Health Popul. Nutr., vol. 25, no. 4, pp. 422–427, 2007.
[6] S. Scida, M. Russo, C. Miraglia, G. Leandro, L. Franzoni, T. Meschi, G. L. De’ Angelis, and F. Di Mario, “Relationship between Helicobacter pylori infection and GERD,” Acta Biomed., vol. 89, no. 8-S, pp. 40–43, 2018.
[7] M. Aburaya, K. Tanaka, T. Hoshino, S. Tsutsumi, K. Suzuki, M. Makise, R. Akagi, and T. Mizushima, “Heme oxygenase-1 protects gastric mucosal cells against nonsteroidal anti-inflammatory drugs,” J. Biol. Chem., vol. 281, pp. 33422–33432, 2006.
[8] M. B. Eswaran, S. Surendran, M. Vijayakumar, S. K. Ojha, A. K. Rawat, and C. Rao, “Gastroprotective activity of Cinnamomum tamala leaves on experimental gastric ulcers in rats,” J. Ethnopharmacol., vol. 128, pp. 537–540, 2010.
[9] P. Sipponen and H. I. Maaroos, “Chronic gastritis,” Scand. J. Gastroenterol., vol. 50, no. 6, pp. 657–667, 2015.
[10] P. Malfertheiner, J. Dent, L. Zeijlon, P. Sipponen, S. J. Veldhuyzen Van Zanten, C. F. Burman, T. Lind, M. Wrangstadh, E. Bayerdörffer, and J. Lonovics, “Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease—Results from a randomized trial programme,” Aliment. Pharmacol. Ther., vol. 16, no. 8, pp. 1431–1442, 2002.
[11] J. P. Gisbert and J. M. Pajares, “Helicobacter pylori infection and perforated peptic ulcer: Prevalence of the infection and role of antimicrobial treatment,” Helicobacter, vol. 8, no. 3, pp. 159–167, 2003.
[12] L. Agréus, N. J. Talley, and M. Jones, “Value of the ‘test & treat’ strategy for uninvestigated dyspepsia at low prevalence rates of Helicobacter pylori in the population,” Helicobacter, vol. 21, no. 3, pp. 186–191, 2016.
[13] T. J. Cleophas and A. H. Zwinderman, SPSS for Starters and 2nd Levelers, 20th ed. Cham, Switzerland: Springer, 2016, p. 375.
[14] J. Jiao and L. Zhang, “Liver involvement by perforated peptic ulcer: A systematic review,” J. Clin. Transl. Pathol., vol. 1, no. 1, pp. 2–8, 2021, doi: 10.14218/jctp.2021.00007.
[15] X. Wang, Z. Wright, J. Wang, W. M. Frandah, and G. Song, “Chronic kidney disease linked to higher incidence of gastric diseases,” Gastrointest. Disord., vol. 5, no. 3, pp. 329–339, 2023, doi: 10.3390/gidisord5030027.
[16] E. Toktay and J. Selli, “Histopathological overview of experimental ulcer models,” Eurasian J. Med., vol. 54, Suppl. 1, pp. S120–S126, 2022, doi: 10.5152/eurasianjmed.2022.22312.
[17] J. G. Kusters, A. H. M. van Vliet, and E. J. Kuipers, “Pathogenesis of Helicobacter pylori infection,” Clin. Microbiol. Rev., vol. 19, no. 3, pp. 449–490, 2006, doi: 10.1128/CMR.00054-05.